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Anterior T-Wave Inversion (ATWI), Present in 
2.3% of Young Whites, More Common in Women 
and in Athletes, 77% Confined to Leads V1 - V2,
Could be a Normal Variant in Asymptomatic 
Individuals Without a Family History of 
Cardiomyopathy or Premature SCD / In Contrast, 
ATWI Extending Beyond V2, Present in only 1% of 
Females and 0.2% in Men, May Justify Further 
Evaluation, Particularly when Preceded by J-Point 
or ST-Segment Depression 
Among 14,646 individuals 16 to 35 years of age,
including 4,720 females (32%) and 2,958 athletes (20%), 
ATWI was detected in 338 individuals (2.3%) and was 
more common in women than in men (4.3% vs. 1.4%, 
respectively; p< 0.0001) and more common among 
athletes than in nonathletes (3.5% vs 2%, respectively; 
p<0.0001). T-wave inversion was predominantly confined 
to leads V1 to V2 (77%). Only 1.2% of women and 0.2% of 
men exhibited ATWI beyond V2. No one with ATWI 
fulfilled diagnostic criteria for ARVC after further 
evaluation. Over 23.1±12.2 months none of the individuals 
with ATWI experienced an adverse event (Malhotra A et 
al, J Am Coll Cardiol 2017;69:1-9).
Alcohol Abuse Increases the Risk of AF, MI, and Heart 
Failure to an Extent Similar to that of Other Strong 
Risk Factors, and Affects Healthier Individuals 
Disproportionately / Protective Effects of Alcohol 
Against MI are Outweighed at Heavy Levels of 
Consumption by its Adverse Effects
Among 14,727,591 patients, 268,084 (1.8%) had 
alcohol abuse, which was associated with an increased risk 
of incident atrial fibrillation (AF) (hazard ratio -HR: 2.14; 
p<0.0001), myocardial infarction (MI) (HR: 1.45; p<
0.0001), and heart failure (HF) (HR: 2.34; p<0.0001). 
Individuals without conventional risk factors for 
cardiovascular disease exhibited a disproportionately 
enhanced risk of each outcome. The population-
attributable risk of alcohol abuse on each outcome was of 
similar magnitude to other well-recognized modifiable risk 
factors (Whitman IR et al, J Am Coll Cardiol 2017;69:13-
24).
LEADERS FREE Trial: in Patients at High Risk of
Bleeding Undergoing PCI Followed by 1 Month of Dual 
Antiplatelet Therapy (DAPT), Polymer-Free Drug-
Coated Stents (DCS) are both Safer and More Effective 
Than Bare Metal Stents (BMS) at 2 Years 
Among 2,466 high bleeding risk patients randomized to
a drug-coated stent (DCS) or a BMS followed by 1-month 
DAPT, at 2 years, the primary safety endpoint (cardiac 
death, MI, or stent thrombosis) had occurred in 147 DCS 
(12.6%) and 180 BMS patients (15.3%) (hazard ratio-HR: 
0.80; p = 0.039). Clinically driven target lesion
revascularization occurred in 77 DCS (6.8%) and 136 
BMS patients (12%) (HR: 0.54; p< 0.0001). Major 
bleeding occurred in 8.9% of DCS and 9.2% of BMS 
patients (p= 0.95), and a coronary thrombotic event (MI
and/or stent thrombosis) occurred in 8.2% of DCS and 
10.6% of BMS patients (p= 0.045). One-year mortality 
was 27.1% for a major bleed and 26.3% for a thrombotic 
event. At 2 years, multivariate correlates of major bleeding 
were age >75 years, anemia, increased creatinine, and 
long-term anticoagulation. Correlates of the primary safety 
endpoint were age, anemia, heart failure, multivessel 
disease, number of stents, and use of a BMS (Garot P et al, 
J Am Coll Cardiol 2017;69:162-171). 
CHAMPION Trials: Cangrelor’s Reduction in
Periprocedural Ischemic Complications Compared 
With Clopidogrel was Maintained Irrespective of GPI 
Use / GPI Use was Associated With Higher Bleeding 
Rates, Regardless of Randomization to Cangrelor or
Clopidogrel
Pooled analysis of the 3 CHAMPION (PCI/ 
PLATFORM/ PHOENIX) trials comprising 24,902 
patients, indicated that among 3,173 patients (12.7%) who 
received a glycoprotein IIb/IIIa inhibitor (GPI), most 
commonly eptifibatide (69.4%), rates of the primary 
composite endpoint (mortality, MI, ischemia-driven 
revascularization, or stent thrombosis at 48 h) were lower 
with cangrelor compared with clopidogrel in patients who 
did (4.9% vs 6.5%; odds ratio - OR: 0.74) or did not receive 
a GPI (3.6% vs 4.4%; OR: 0.82; Pint= 0.55). Cangrelor did 
not increase the primary safety endpoint, severe/life-
threatening bleeding, in patients who did (0.4% vs. 0.5%;
OR: 0.71) or did not receive GPIs (0.2% vs. 0.1%; OR: 
1.56; Pint= 0.21). GPI use was associated with increased 
risk of bleeding in both treatment arms (Vaduganathan M, 
et al, J Am Coll Cardiol 2017;69:176-185). 
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Left Atrial Appendage Closure (LAAC): Reported 
Rate of Procedure-Related Complications has 
been Low (Tamponade ~1% & Mortality <0.1%)
After FDA Approval of the LAAC Device, Despite 
that ~70% of the Implanters Were Previously 
Inexperienced With the Procedure
After FDA approval (March 2015) of the left atrial 
appendage closure (LAAC) (Watchman) device, 
among 3,822 consecutive AF cases, implantation was 
successful in 3,653 (95.6%), with a median procedure 
time of 50 min (10 - 210 min). Implanting physicians 
(n= 382) included 71% new, nonclinical trial 
implanters, who performed 50% of the procedures. 
Procedural complication rates comprised 39 
pericardial tamponades (1.02%) (24 treated 
percutaneously, 12 surgically, and 3 fatal); 3 
procedure-related strokes (0.078%); 9 device 
embolizations (0.24%) (6 requiring surgical 
removal); and 3 procedure-related deaths (0.078%)
(Reddy VY et al, J Am Coll Cardiol 2017;69:253-261.). 
Ablating Areas with Spatiotemporal Dispersion of
Multipolar Electrograms, Presumed Identifiers of
Electrical Drivers, May Eliminate AF
In 105 AF patients, AF was mapped in both atria with 
a 20-pole PentaRay catheter and regions displaying 
electrogram dispersion during AF were identified and 
ablated. Ablation at dispersion areas (presumed to be at the 
vicinity of a driver), without PVI, terminated AF in 95% 
of patients (to SR in 15% or atrial tachycardia-AT in 80%).
Subsequent mapping and ablation of ~1.9 ATs per patient 
resulted in an overall ablation to SR in 77% vs ~20% for 
the validation set. Over 18 months, arrhythmia recurrence
rate was 15% after 1.4±0.5 procedures per patient vs 41% 
in the validation set after 1.5±0.5 procedures per patient 
(arrhythmia free-survival: 85% vs 59%; log-rank p<
0.001). Compared with the validation set, radiofrequency 
times (49±21 min vs 85±34.5 min; p=0.001) and procedure 
times (168±42 min vs 230±67 min; p<0.0001) were shorter
(Seitz J et al, J Am Coll Cardiol 2017;69:303-321).
In Older Hypertensive Patients, Intensive BP Control 
(<140 mmHg) Reduces MACE, Cardiac Mortality, and 
HF, But May Increase Risk of Renal Failure
Meta-analysis of 4 trials involving 10,857 older 
hypertensive patients with a mean follow-up of 3.1 years,
indicated that intensive BP lowering was associated with a 
29% reduction in MACE (RR: 0.71), 33% in cardiovascu-
lar mortality (RR: 0.67), and 37% in heart failure (RR: 
0.63) compared with standard BP lowering. Rates of MI
and stroke did not differ between the 2 groups. There was 
no significant difference in the incidence of serious 
adverse events (RR: 1.02) or renal failure (RR: 1.81). The 
fixed effects model yielded largely similar results, except 
for an increase in the risk of renal failure (RR: 2.03) with 
intensive BP-lowering therapy (Bavishi C et al, J Am Coll 
Cardiol 2017;69:486-493). 
Exercise-Induced Arrhythmogenic Remodeling 
(EIAR) vs Arrhythmogenic Right Ventricular 
Cardiomyopathy (ARVC): Isolated Subepicardial
RVOT Scar as a VT Substrate in Endurance Athletes 
that can be Treated by Ablation
In 57 patients (mean age 48 ± 16 years; 83% male) 
undergoing catheter ablation for scar-related right 
ventricular VT, 2 distinct scar distributions were 
identified: scars involving the subtricuspid right ventricle 
in 46 patients (group A); and scars restricted to the anterior 
subepicardial RVOT in 11 patients (group B, all high-level 
endurance athletes). ARVC or post-inflammatory 
cardiomyopathy was diagnosed in 40 (87%) of 46 group A 
patients but none in group B. Scar-related VTs were 
significantly faster in group B patients (257 ± 34 ms vs 328 
± 72 ms in group A; p=0.003). Catheter ablation resulted 
in complete procedural success in 10 (91%) of 11 group B 
patients vs 26 (57%) of 46 group A patients (p= 0.034). 
During a median of 27 months, 50% of group A patients 
but none of the group B patients had a VT recurrence 
(Venlet J et al, J Am Coll Cardiol 2017;69:497-507). 
High-dose NOACs Provide Overall Efficacy and Safety 
Similar in AF Patients with or without Valvular Heart 
Disease (VHD) (other than Moderate/Severe Mitral 
Stenosis or Mechanical Heart Valves)
According to a meta-analysis of the 4 phase III AF trials 
of NOACs vs warfarin in patients with coexisting VHD,
compared with warfarin, the rate of thromboembolism in 
patients treated with higher-dose NOACs was lower and 
consistent among 13,585 patients with (RR:0.70) or 
58,098 without VHD (RR: 0.84; p = 0.13). Major bleeding 
in patients on higher-dose NOACs vs warfarin was similar 
and consistent among patients with (RR: 0.93) or without 
VHD (RR: 0.85). Intracranial hemorrhage was lower with 
higher-dose NOACs than with warfarin irrespective of 
VHD (RR: 0.47, & 0.49, respectively; p=0.91). No prote-
ctive effect of higher-dose NOACs in preventing all-cause 
death was present in patients with VHD vs without VHD
(Renda G et al, J Am Coll Cardiol 2017;69:1363-1371).
Catheter-Based Radiofrequency Renal Denervation 
(RDN) in Sheep with Hypertensive Chronic Kidney 
Disease (CKD) Compromised the Compensatory 
Hemodynamic Response to Hemorrhage
RDN in sheep caused a complete reversal of 
hypertension and improved renal function in CKD-RDN 
(n=7) sheep (p< 0.0001 for 2 and 5 months vs pre-RDN). 
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In response to hemorrhage, mean arterial pressure fell in 
all groups, with greater fall in the RDN (n=15) than the 
intact (n=13) group (p<0.001). Hemorrhage increased 
heart rate and plasma renin activity in intact sheep, but 
these responses were significantly attenuated in control-
RDN (n=8) and CKD-RDN (n=7) animals. Responses to 
hemorrhage were remarkably similar at 2 and 5 months 
post-RDN, which suggests that nerve function had not 
returned within this time frame (Singh RR et al, J Am Coll 
Cardiol 2017;69:951-964). 
PEITHO Trial: Systemic Thrombolysis for Pulmonary 
Embolism (PE) in Normotensive Patients With RV 
Dysfunction (Intermediate-Risk PE) did not Confer a 
Benefit / Thus, a Strategy of Anticoagulation, Early 
Monitoring, and Rescue Reperfusion in Cases of 
Hemodynamic Decompensation is Preferable
In the PEITHO trial, long-term (median 37.8 months) 
survival was assessed in 353 of 359 (98.3%) patients in the 
thrombolysis arm and in 343 of 350 (98.0%) in the placebo 
arm. Overall mortality rates were 20.3% and 18%, 
respectively (p=NS). Between day 30 and long-term
follow-up, 65 deaths occurred in the thrombolysis arm and 
53 occurred in the placebo arm. At follow-up examination 
of survivors, persistent dyspnea or functional limitation 
was reported by 36% vs 30.1% of the patients (p = NS). 
Echocardiography (performed in 144 and 146 patients, 
respectively) did not reveal significant differences in 
residual pulmonary hypertension or RV dysfunction. 
Chronic thromboembolic pulmonary hypertension was 
confirmed in 4 (2.1%) vs 6 (3.2%) cases (p= NS) (Konsta-
ntinides SV et al, J Am Coll Cardiol 2017;69: 1536-1544). 
Meta-Analysis of TAPAS, TASTE & TOTAL: Routine 
Thrombus Aspiration During PCI for STEMI did not 
Improve Clinical Outcomes / In the High Thrombus 
Burden Group, there were Trends Toward Reduced 
Cardiovascular Death and Increased Stroke or TIA 
Meta-analysis of 3 randomized thromboaspiration trials 
(TAPAS, TASTE, TOTAL) comprising ௗSDWLHQWVRI
ZKRPௗXQGHUZHQW3&,indicated that cardiovascular 
death at 30 days occurred in 221 of 9155 patients (2.4%) 
randomized to thrombus aspiration and 262 of 9151 (2.9%) 
randomized to PCI alone (hazard ratio - HR, 0.84; P=0.06). 
Stroke or TIA occurred in 66 (0.8%) randomized to 
thrombus aspiration and 46 (0.5%) randomized to PCI 
alone (odds ratio-OR, 1.43; P=0.06). There were no 
significant differences in recurrent MI, stent thrombosis, 
heart failure, or target vessel revascularization. In the 
subgroup with high thrombus burden, thrombus aspiration 
was associated with fewer cardiovascular deaths (170 
[2.5%] vs 205 [3.1%]; hazard ratio, 0.80; P=0.03) and with 
more strokes or TIAs (55 [0.9%] vs 34 [0.5%]; OR, 1.56, 
P=0.04) (Jolly SS et al, Circulation 2017;135:143-152).
Meta-Analysis of All the Published Randomized 
Controlled Trials (RCTs) To Date Demonstrates
Significant Clinical Benefit on All-Cause Mortality in 
Favor of ICD Use for Primary Prevention in Patients 
With Non-Ischemic Cardiomyopathy (NICM)
Updated meta-analysis of 6 RCTs enrolling 2970 
patients with NICM studying the efficacy of ICDs for 
primary prevention demonstrated a statistically significant 
23% risk reduction in all-cause mortality in favor of ICD 
therapy (hazard ratio-HR, 0.77). In addition, when separate 
analysis of trials that assessed ICD plus optimal medical 
therapy (OMT) vs OMT alone (after exclusion of CRT-D
trials) was performed, a statistically significant 24% 
reduction was found in all-cause mortality with ICD (HR,
0.76). When the 2 trials, COMPANION and DANISH-
CRT subgroup with ICD plus CRT plus OMT vs CRT plus 
OMT alone were compared, a trend was found toward 
benefit in terms of all-cause mortality in the ICD group, 
although it did not meet statistical significance (HR, 0.70)
(Golwala H et al, Circulation 2017; 135:201–203).
PIONEER Study / Post Hoc Analysis: Among Patients 
With AF Undergoing Intracoronary Stenting, Admini-
stration of Either Rivaroxaban 15 mg qd Plus P2Y12
Inhibitor Monotherapy (Group 1) or 2.5 mg 
Rivaroxaban bid Plus DAPT (Group 2) was Associated 
With a Reduced Risk of All-Cause Mortality or
Recurrent Hospitalization Compared With Standard-
Of-Care VKA Plus DAPT (Group 3) 
Among stented subjects with AF (n=2124), the risk of 
all-cause mortality or recurrent hospitalization was 34.9% 
in group 1 (hazard ratio-HR=0.79; P=0.008 vs group 3; 
number needed to treat=15), 31.9% in group 2 (HR=0.75;
P=0.002 vs group 3; number needed to treat=10), and 
41.9% in group 3 (VKA+DAPT). Both all-cause death 
plus hospitalization potentially resulting from bleeding 
(group 1=8.6%, P=0.032 vs group 3, group 2=8%,
P=0.012 vs group 3, and group 3=12.4%) and all-cause 
death plus rehospitalization potentially resulting from a 
cardiovascular cause (group 1=21.4%, P=0.001 vs group 
3; group 2=21.7%, P=0.011 vs group 3, and group 
3=29.3%) were reduced in the rivaroxaban arms compared 
with the VKA arm, but other forms of rehospitalization 
were not (Gibson CM, Circulation 2017;135:323-333). 
MIDA Registry: Among Patients With Degenerative 
Mitral Regurgitation With a Flail Leaflet Referred to
Mitral Surgery, MV Repair was Associated With 
Lower Operative Mortality, Better Long-Term 
Survival, and Fewer Valve-Related Complications 
Compared With MV Replacement (MVR)
Patients undergoing MV repair (n=1709) were younger, 
had more comorbidities, and were more likely to present 
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with a posterior leaflet prolapse than those undergoing 
MVR (n=213). After propensity score matching, operative 
mortality was lower after MV repair than after replacement
in both the entire population (1.3% vs 4.7%; P<0.001) and 
the propensity-matched population (0.2% vs 4.4%;
P<0.001). During a mean of 9.2 years, 552 deaths were
observed, of which 207 cardiovascular; 20-year survival 
was better after MV repair than after MVR in both the 
entire population (46% vs 23%; P<0.001) and the matched 
population (41% vs 24%; P<0.001). Similar superiority of 
MV repair was obtained in patient subsets on the basis of 
age, sex, or any stratification criteria (all P<0.001). MV 
repair was also associated with reduced incidence of 
reoperations and valve-related complications (Lazam S et 
al; Circulation 2017;135:410-422).
Genetic Obesity and the Risk of Atrial Fibrillation
(AF): Data are Consistent With a Causal Relationship 
Between BMI and Incident AF
In age- and sex-adjusted meta-analysis among ௗ
individuals of European ancestry without AF at baseline, 
both genetic instruments (FTO genotype & a BMI gene 
score) were significantly associated with BMI (FTO: 0.43
kg/m2 per A-allele, P<0.001; BMI gene score: 1.05 kg/m2
per 1-U increase, P<0.001) and incident AF (FTO, hazard 
ratio-HR, 1.07 per A-allele, P=0.004; BMI gene score, HR, 
1.11 per 1-U increase, P<0.001). Age- and sex-adjusted 
instrumental variable estimates for the causal association 
between BMI and incident AF were HR, 1.15 per kg/m2,
P=0.005 (FTO) and 1.11 per kg/m2, P<0.001 (BMI gene 
score). Both these estimates were consistent with the meta-
analyzed estimate between observed BMI and AF. Multi-
variable adjustment did not significantly change findings
(Chatterjee NA et al, Circulation 2017;135:741-754). 
Brain Emboli After Left Ventricular Endocardial 
Ablation: 58% of Patients Having Routine LV Ablation
Experienced New Brain Emboli After the Procedure
Among 18 patients undergoing left (n=12) or right 
(n=6) ventricular ablation for VT or PVCs over a 9-month 
period, 7 (58%) undergoing LV ablation experienced a 
total of 16 cerebral emboli detected by MRI, in comparison 
with zero patients undergoing right ventricular ablation 
(P=0.04). 7 of 11 patients (63%) undergoing a retrograde 
approach to the LV developed at least 1 new brain lesion
(Whitman IR et al; Circulation 2017;135:867-877). 
STICH Trial: The Monthly Risk of Sudden Death 
(SCD) Shortly After CABG Among Patients with Low 
Ejection Fraction is Highest Between First & Third 
Months, Suggesting That Risk Stratification for SCD 
Should Occur Early in the Postoperative Period
Over a median of 46 months, 113 of 1411 patients who 
received CABG without (n=934) or with (n=477) surgical 
ventricular reconstruction had SCD. The mean LVEF at 
enrollment was 28±9%. The 5-year cumulative incidence 
of SCD was 8.5%. Patients who had SCD and those who 
did not die were younger and had fewer comorbid 
conditions than did those who died of causes other than 
SCD. In the first 30 days after CABG, SCD (n=5) 
accounted for 7% of all deaths. The numerically greatest 
monthly rate of SCD was in the 31- to 90-day time period. 
In a multivariable analysis, end-systolic volume index and 
B-type natriuretic peptide were most strongly associated 
with SCD (Rao MP, Circulation 2017;135:1136-1144). 
MOMENTUM 3: Among Patients With Advanced 
Heart Failure, Implantation of a Fully Magnetically 
Levitated Centrifugal-Flow Pump was Associated With 
Better Outcomes at 6 Months Than was Implantation 
of an Axial-Flow Pump, Primarily Because of the 
Lower Rate of Reoperation for Pump Malfunction
Of 294 patients, 152 were assigned to the centrifugal-
flow pump group and 142 to the axial-flow pump group. 
In the intention-to-treat population, the primary end point 
(survival free of disabling stroke or reoperation) occurred 
in 131 patients (86.2%) in the centrifugal-flow pump group 
and in 109 (76.8%) in the axial-flow pump group (P<0.001 
for noninferiority; hazard ratio, 0.55; two-tailed P=0.04 for 
superiority). There were no significant between-group 
differences in the rates of death or disabling stroke, but 
reoperation for pump malfunction was less frequent in the 
centrifugal-flow pump group than in the axial-flow pump 
group (Mehra MR et al, N Engl J Med 2017; 376:440-450). 
No Device/Lead Failure During Nonthoracic MRI (1.5 
Tesla) for Non–MRI-Conditional Pacemakers or ICDs
MRI was performed in 1000 pacemaker cases and 500 
ICD cases. No deaths, lead failures, losses of capture, or 
ventricular arrhythmias occurred during MRI. One ICD 
generator could not be interrogated after MRI and required 
immediate replacement; the device had not been 
appropriately programmed per protocol before the MRI. 
There were observed 6 cases of self-terminating atrial
fibrillation or flutter and 6 cases of partial electrical reset. 
Changes in lead impedance, pacing threshold, battery 
voltage, and P-wave and R-wave amplitude exceeded 
prespecified thresholds in a small number of cases. Repeat 
MRI was not associated with an increase in adverse events. 
(Rousso RJ et al, N Engl J Med 2017; 376:755-764). 
COMPARE-ACUTE Trial: In Patients With STEMI 
and Multivessel Disease Who Underwent Primary PCI 
of an Infarct-Related Artery, the Addition of FFR
Resulted in a Lower Risk (Mainly Reduction in 
Subsequent Revascularizations) 
Among 885 patients with STEMI and multivessel 
disease who underwent primary PCI of an infarct-related 
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artery randomized to undergo complete revascularization 
of non–infarct-related arteries guided by fractional flow 
reserve (FFR) (295 patients) or to undergo no 
revascularization of non–infarct-related arteries (590 
patients), the primary outcome (death from any cause,
nonfatal MI, revascularization, and cerebrovascular events 
at 12 months) occurred in 23 patients in the complete-
revascularization group and in 121 patients in the infarct-
artery-only group that did not receive complete 
revascularization (hazard ratio-HR, 0.35; P<0.001). Death 
occurred in 4 patients in the complete-revascularization 
group and in 10 patients in the infarct-artery-only group 
(1.4% vs. 1.7%) (HR, 0.80), MI in 7 and 28 patients, 
respectively (2.4% vs 4.7%) (HR, 0.50), revascularization 
in 18 and 103 patients (6.1% vs 17.5%) (HR, 0.32), and 
cerebrovascular events in 0 and 4 patients (0 vs 0.7%). An 
FFR-related serious adverse event occurred in 2 patients 
(both in the group receiving infarct-related treatment only) 
(Smits PC et al, N Engl J Med 2017; 376:1234-1244).
Novel Insights into the Mechanism Through Which
Emotional Stressors Can Lead to Cardiovascular 
Disease (CVD) in Humans via a Link of Regional Brain 
Activity: Amygdalar Activity Independently and 
Robustly Predicted CVD Events, Partly Via a Path that 
Includes Increased Bone-Marrow Activity and Arterial 
Inflammation
Of 293 patients (median age 55 years), 22 had a CVD
event during median follow-up of 3.7 years. Amygdalar 
activity was associated with increased bone-marrow 
activity (r=0·47; p<0·0001), arterial inflammation 
(r=0·49; p<0·0001) (all assessed via PET/CT), and risk of 
CVD events (hazard ratio 1.59; p<0·0001), a finding that 
remained significant after multivariate adjustments. The 
association between amygdalar activity and CVD events 
seemed to be mediated by increased bone-marrow activity 
and arterial inflammation in series. In 13 patients who 
underwent psychometric analysis, amygdalar activity was 
significantly associated with arterial inflammation 
(r=0·70; p=0·0083). Perceived stress was associated with 
amygdalar activity (r=0·56; p=0·0485), arterial 
inflammation (r=0·59; p=0·0345), and C-reactive protein 
(r=0·83; p=0·0210) (Tawakol A et al, Lancet 2017;
389(10071):834-845).
Important Review and Other Articles 
HIV and heart disease (Vachiat A et al / Manga P et al, 
J Am Coll Cardiol 2017;69:73-81 & 83-91), Cardiac 
pacemakers (Mulpuru SK et al/ Madhavan M et al J Am 
Coll Cardiol 2017;69:189-210 / 211-235), Challenges in 
infective endocarditis (Cahill TJ et al, J Am Coll Cardiol
2017;69:325-344), Appropriate use criteria for 
revascularization in acute coronary syndromes (Patel MR 
et al, J Am Coll Cardiol 2017;69::570-591), Mode of death 
in heart failure with preserved ejection fraction
(Vaduganathan M et al, J Am Coll Cardiol 2017;69:556-
569), 2016 AHA/ACC clinical performance and quality
measures for prevention of sudden cardiac death (Al-
Khatib SM et al, J Am Coll Cardiol 2017;69:712-744), 
Sleep apnea & cardiovascular consequences (Javaheri S et 
al, J Am Coll Cardiol 2017;69:841-858), Carcinoid heart 
disease diagnosis and management (Davar J et al, J Am 
Coll Cardiol 2017;69:1288-1304), 2017 ACC Expert 
Consensus on TAVI (Otto CM et al, J Am Coll Cardiol
2017;69:1313-1346), 2016 AHA/ACC Guideline on the 
management of patients with lower extremity peripheral 
artery disease (Gerhard-Herman MD et al, J Am Coll 
Cardiol 2017;69:1465-1508), Coronary anomalies 
(Cheezum MK et al, J Am Coll Cardiol 2017;69:1592-
1608), Cardiovascular effects of performance-enhancing 
drugs (La Gerche et al, Circulation 2017;135:89-99),
Management of pregnancy in patients with complex 
congenital heart disease (Canobbio MM et al, Circulation
2017;135:e50-e87), AHA Scientific Statement on Meal 
timing and frequency: Implications for cardiovascular 
disease prevention (St-Onge M-P et al, Circulation 2017; 
135:e96-e121), Heart disease and stroke statistics 2017 
(Benjamin EJ et al, Circulation 2017;135:e146-e603), 
Management of patients on NOACs in acute care and peri-
procedural setting (Raval AN et al, Circulation 2017;e604-
633), Non-obstructive coronary artery disease (Merz CNB 
et al, Circulation 2017;135:1075-1092), Telemedicine in 
pediatric cardiology (Satou GM et al, Circulation 2017; 
135:e648-e678), Arrhythmogenic right ventricular 
cardiomyopathy (Corrado D et al, N Engl J Med 2017; 
376:61-72), Hypertrophic cardiomyopathy (Veselka J et 
al, Lancet 2017;389(10075):1253-1267), Acute MI (Reed 
GW et al, Lancet 2017; 389(10065):197-210), Natriuretic 
peptides in acute heart failure (McQuade CN et al, Ann 
Intern Med 2017;166:180-190), Benefits and harms of 
intensive blood pressure treatment (Weiss J et al, Ann 
Intern Med 2017; 166:419-429).
Just in (ACC’17)! SURTAVI: TAVI was a Noninferior 
Alternative to Surgery in Patients With Severe Aortic 
Stenosis (AS) at Intermediate Surgical Risk
Among 1660 intermediate-risk AS patients (aged 
79.8±6.2 years) undergoing TAVI (self-expanding pros-
thesis) or surgery, at 24 months, death or stroke incidence
was 12.6% in the TAVI group and 14% in the surgery 
group. Surgery was associated with higher rates of acute 
kidney injury, AF, and transfusion requirements, whereas 
TAVI had higher rates of residual aortic regurgitation and 
need for pacemaker implantation. TAVI resulted in lower 
mean gradients and larger aortic-valve areas than surgery 
(Reardon MJ, N Engl J Med 2017;376:1321-1331). 
